


FXIa-IN-10

Cat. No.:	HY-151196
CAS No.:	2816108-08-2
Molecular Formula:	C ₂₃ H ₁₈ Cl ₂ F ₃ N ₉ O ₂
Molecular Weight:	580.35
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	FXIa-IN-10 (Compound 3f) is a potent activated factor XI (FXIa) inhibitor with an K _i of 0.17 nM. FXIa-IN-10 has good oral bioavailability ^[1] .								
IC₅₀ & Target	K _i : 0.17 nM (FXIa) ^[1]								
In Vivo	<p>FXIa-IN-10 (Compound 3f) (1.7+2.0 and 8.5+10.0 (bolus + infusion) mg/kg; i.v.; twice) shows antithrombotic efficacy in a rabbit AV shunt thrombosis model^[1].</p> <p>FXIa-IN-10 (0-10 mg/kg; p.o.; once) demonstrates oral bioavailability in preclinical species (rat 36.4%, dog 80.5%, and monkey 43.0%)^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>								
	Animal Model:	Male New Zealand White (NZW) rabbits, AV shunt thrombosis model ^[1]							
	Dosage:	1.7+2.0 and 8.5+10.0 (bolus + infusion) mg/kg							
	Administration:	Intravenous injection, 20 min prior to and 40 min during the AV shunt							
	Result:	Reduced thrombus weights in a dose-dependent manner.							
	Animal Model:	Sprague-Dawley rats, Beagle dogs, Cynomolgus monkeys ^[1]							
	Dosage:	1, 2, 5 or 10 mg/kg							
	Administration:	Intravenous or oral administration (Pharmacokinetic Analysis)							
	Result:	Pharmacokinetic Profile of FXIa-IN-10 (Compound 3f) in Preclinical Species ^{a[1]}							
		animal species	clearance (mL/min/kg)	T _{1/2} (h)	V _{dss} (L/kg)	F%	AUC (iv) (μM·h)	AUC (po) (μM·h)	Dose iv/po (mpk)

rat	10.7 ± 1.8	1.4 ± 0.0	0.8 ± 0.1	36.4	5.5 ± 1.0	10.0 ± 2.4	2/10
monkey	25.6 ± 4.0	1.0 ± 0.4	1.5 ± 0.4	43.0	1.1 ± 0.2	2.5 ± 0.3	1/5

^aCompound was dosed as a free base, vehicle for iv: 20% HPβCD and po: 10% ethanol; 70% PEG-400; 20% water. Data were derived from three animals per study.

REFERENCES

[1]. Xu G, et al. Discovery of Potent and Orally Bioavailable Pyridine N-Oxide-Based Factor XIa Inhibitors through Exploiting Nonclassical Interactions. J Med Chem. 2022 Aug 11;65(15):10419-10440.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA